New agents in cancer clinical trials
New agents in cancer clinical trials
复制标题
DOI：
10.1038/sj.onc.1204088
复制
发表时间：
2000-12-27
期刊：
影响因子：
8
通讯作者：
Elliott, PJ
中科院分区：
文献类型：
--
作者：
Adams, J;Elliott, PJ
随着现代技术的进步和对细胞生物学的日益了解，目前正在寻求各种新的机制和分子拮抗剂来对抗癌症。这些进展的结果催生了数十种新的令人兴奋的小分子药物，这些药物正在通过艰难的临床试验过程中缓慢发展。我们试图在这篇评论中强调一些新的和令人兴奋的分子代表以前未开发的目标。虽然这是不确定的，在一个分子靶点的新奇性，确保它是一个很好的，我们的阅读目前的文献表明，在这篇评论中讨论的七个分子代表潜在的新疗法，可能会增加急需的医疗设备的癌症药物（图1）。
With advances in modern technologies and growing understanding of cellular biology, a variety of new mechanisms and molecular antagonists are currently being pursued in the fight against cancer. The result of these advances has spawned dozens of new exciting small molecule agents which are slowly progressing through the arduous process of clinical trials. We attempt in this review to highlight some of the new and exciting molecules representing previously unexplored targets. While it is by no means certain that novelty in a molecular target assures that it is a good one, our reading of the current literature would suggest that the seven molecules discussed in this review represent potentially new therapies which may add to the much needed armamentarium of cancer drugs (Figure 1).